Buscar
Mostrando ítems 1-10 de 13
Artículo
![Con acceso al texto completo Icon](/themes/idUS//images/acceso/opened_access.png)
Aripiprazole as a candidate treatment of COVID-19 identified through genomic analysis
(Frontiers Media SA, 2021)
Background: Antipsychotics modulate expression of inflammatory cytokines and inducible inflammatory enzymes. Elopiprazole (a phenylpiperazine antipsychotic drug in phase 1) has been characterized as a therapeutic drug to ...
Artículo
![Con acceso al texto completo Icon](/themes/idUS//images/acceso/opened_access.png)
Treatment Discontinuation Impact on Long-Term (10-Year) Weight Gain and Lipid Metabolism in First-Episode Psychosis: Results From the PAFIP-10 Cohort
(CAMBRIDGE UNIV. PRESS, 2021)
Background: Patients with a first episode of psychosis (FEP) are at higher risk of gaining weight and presenting metabolic disturbances, partly related to antipsychotic exposure. Previous studies suggest that treatment ...
Artículo
![Con acceso al texto completo Icon](/themes/idUS//images/acceso/opened_access.png)
Prevalence of metabolic syndrome and related factors in a large sample of antipsychotic naïve patients with first-episode psychosis: Baseline results from the PAFIP cohort
(Elsevier Science BV, 2022)
Background: Few investigations have been carried out on metabolic syndrome in antipsychotic- naïve patients with schizophrenia. Methods: Our primary objective was to compare the prevalence of Metabolic Syndrome (MetS), ...
Artículo
![Con acceso al texto completo Icon](/themes/idUS//images/acceso/opened_access.png)
Expression and Functionality Study of 9 Toll-Like Receptors in 33 Drug-Naïve Non-Affective First Episode Psychosis Individuals: A 3-Month Study
(MDPI, 2020)
Toll-like receptors (TLRs) are a pivotal component of the innate immune system that seem to have a role in the pathogenesis of psychosis. The purpose of this work was to compare the expression and functionality of 9 TLRs ...
Artículo
![Con acceso al texto completo Icon](/themes/idUS//images/acceso/opened_access.png)
Polygenic risk scores enhance prediction of body mass index increase in individuals with a first episode of psychosis
(ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER, 2023)
Background. Individuals with a first episode of psychosis (FEP) show rapid weight gain during the first months of treatment, which is associated with a reduction in general physical health. Although genetics is assumed ...
Artículo
![Con acceso al texto completo Icon](/themes/idUS//images/acceso/opened_access.png)
Peripheral lymphocyte signaling pathway deficiencies predict treatment response in first-onset drug-naïve schizophrenia
(ACADEMIC PRESS INC ELSEVIER SCIENCE, 2022)
Despite being a major cause of disability worldwide, the pathophysiology of schizophrenia and molecular basis of treatment response heterogeneity continue to be unresolved. Recent evidence suggests that multiple aspects ...
Artículo
![Con acceso al texto completo Icon](/themes/idUS//images/acceso/opened_access.png)
Pattern of long-term weight and metabolic changes after a first episode of psychosis Results from a 10-year prospective follow-up of the PAFIP program for early intervention in psychosis cohort
(Cambridge University Press, 2022-08-16)
Background People with psychosis are at higher risk of cardiovascular events, partly explained by a higher predisposition to gain weight. This has been observed in studies on individuals with a first-episode psychosis ...
Artículo
![Con acceso al texto completo Icon](/themes/idUS//images/acceso/opened_access.png)
Gene set enrichment analysis of pathophysiological pathways highlights oxidative stress in psychosis
(Springer Nature, 2022-09-21)
Polygenic risk prediction remains an important aim of genetic association studies. Currently, the predictive power of schizophrenia polygenic risk scores (PRSs) is not large enough to allow highly accurate discrimination ...
Artículo
![Con acceso al texto completo Icon](/themes/idUS//images/acceso/opened_access.png)
Aripiprazole vs Risperidone Head-to-Head Effectiveness in First-Episode Non-Affective-Psychosis: A 3-Month Randomized, Flexible-Dose, Open-Label Clinical Trial
(Oxford University Press, 2022-07-27)
Background Antipsychotic choice for the acute phase of a first episode of psychosis (FEP) is of the utmost importance since it may influence long-term outcome. However, head-to-head comparisons between second-generation ...
Artículo
![Con acceso al texto completo Icon](/themes/idUS//images/acceso/opened_access.png)
Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone
(Oxford University Press, 2020)
Background: Different effectiveness profiles among antipsychotics may be a key point to optimize treatment in patients suffering a first episode of psychosis to impact on long-term outcome. The aim of this study is to ...